OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial (CROSBI ID 178389)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Diener, H.C. ; Dodick, D.W. ; Aurora, S.K. ; Turkel, C.C. ; DeGryse, R.E. ; Lipton, R.B. ; Silberstein, S.D. ; Brin, M.F. ; PREEMPT 2 Chronic Migraine Study Group ; Becker, W.J. ; Blumenfeld, A. ; Cutrer, F.M. ; Gendolla, A. ; Lay, C. ; Martin, V. ; Relja, Maja ; Schim, J.D. ; Smith, T.R. ; Ward, T.W. ; Winner, P.
engleski
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
The results of PREEMPT 2 demonstrate that onabotulinumtoxinA is effective for prophylaxis of headache in adults with chronic migraine. Repeated onabotulinumtoxinA treatments were safe and well tolerated.
chronic migraine; onabotulinumtoxinA; prophylaxis
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Kliničke medicinske znanosti
